Cyclosporine enhances platelet procoagulant activity

Nephrology Dialysis Transplantation

Volumn 22, Issue 6, 2007, Pages 1750-1756

  Tomasiak, Marian ^a   Rusak, Tomasz ^a   Gacko, Marek ^a   Stelmach, Halina ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Cyclosporine; Phosphatidylserine; Plasma membrane; Platelets procoagulant activity

Indexed keywords

COLLAGEN; CYCLOSPORIN A; FLUORESCEIN ISOTHIOCYANATE; LACTATE DEHYDROGENASE; LIPOCORTIN 5; PHOSPHATIDYLSERINE; THROMBIN;

ARTICLE; CELL POPULATION; CONTROLLED STUDY; CYTOTOXICITY; DOSE TIME EFFECT RELATION; ENZYME RELEASE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYPOTHESIS; IN VITRO STUDY; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTE MEMBRANE; THROMBOCYTE STRUCTURE; THROMBOEMBOLISM; THROMBOGENESIS;

ANIMALS; BLOOD COAGULATION; BLOOD PLATELETS; CELL MEMBRANE; COLLAGEN; CYCLOSPORINE; HORSES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIGHT; MICE; PHOSPHATIDYLSERINES; PLATELET ACTIVATION; SCATTERING, RADIATION; THROMBIN;

EID: 34447577028     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl836     Document Type: Article

References (36)

1. Kahan BD. Cyclosporine. N Engl J Med 1989; 321: 1725-1738
2. Mahony JF, Caterson RJ, Pollock CA, Jones M, Waugh DA, Sheil AGR. Coronary artery disease is the major late complication of successful cadaveric renal transplantation. Clin Transplant 1990; 4: 129-131
3. Remuzzi G, Bertrani T. Renal vascular and thrombotic effects of cyclosporine. Am J Kidney Dis 1989; 13: 261-272
4. Brunkwall J, Bergqvist D, Bergentz SE, Bornmyr S, Husberg B. Postoperative deep venous thrombosis after renal transplantation. Effects of cyclosporine. Transplantation 1987; 43: 647-649
5. Weidle PJ, Vlasses PH. Systemic hypertension associated with cyclosporine. Drug Intell Clin Pharmacol 1988; 22: 443-450
6. Bossaler C, Forstermann U, Hertel R, Olbricht C, Reschke V, Fleck E. Cyclosporin A inhibits endothelium-dependent vasodilation and vascular prostacyclin production. Eur J Pharmacol 1989; 165: 165-169
7. Dudhir K, MacGregor JS, DeMarco T et al. Cyclosporine impairs release of endothelium-derived relaxing factors in epicardial and resistrance coronary arteries. Circulation 1994; 90: 3018-3023
8. Jorkasky DK, Fisher CA, Stahl RF, Addonizio VP, Glickman JD. The effects of cyclosporine on human platelet aggregation and thromboxane release. Transplant Proc 1989; 21: 948-949
9. Cohen H, Neild GH, Patel R, Mackie IJ, Machin SJ. Evidence for chronic platelet hyperaggregability and in vivo activation in cyclosporine-treated renal allograft recipients. Thromb Res 1989; 49:91-101
10. Fernandes JB, Naik UP, Markell MS, Kornecki E. Comparative investigation of the effects of the immunosuppresants cyclosporine A, cyclosporine G and FK-506 on platelet activation. Cell Mol Biol Res 1993; 39: 265-274
11. Fishman SJ, Wylonis LJ, Glickman JD et al. Cyclosporin A augments human platelet sensitivity to aggregating agents by increasing fibrinogen receptor availability. J Surg Res 1991; 51: 93-98
12. Heemskerk J, Bevers E, Lindhout T. Platelet activation and blood coagulation. Thromb Haemost 2002; 88: 186-193
13. Zwaal R, Comfurius P, Bevers EM. Lipid-protein interactions in blood coagulation. Biochim Biophys Acta 1998; 1376: 433-453
14. Zwaal RFA, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 1997; 4: 1121-1132
15. Lambros MP, Rahman YE. Effects of cyclosporin A on model lipid membranes. Chem Phys Lipids 2004; 131: 63-69
16. Schote U, Ganz P, Fahr A, Seeling J. Interactions of cylosporines with lipid membranes as studied by solid-state nuclear magnetic resonance spectroscopy and high-sensitivity titration calorimetry. J Pharm Sci 2002: 91: 856-867
17. Bruzgo I, Tomasiak M, Stelmach H, Midura-Nowaczek K. The effect of some ε-aminocaproic acid derivatives on platelet responses. Acta Biochim Polon 2004; 51: 73-80
18. Rota S, Flynn PD, Wareham NJ, Baglin TP. Is platelet phospholipid-dependent thrombin generation altered by acute myocardial infarction or aspirin? Thromb Res 1996; 83: 329-338
19. + exchanger in the formation of microvesicles by porcine blood platelets. Haematologia 2002; 32: 239-252
20. Bergmeyer HU. Methods of Enzymatic Analysis. Verlag Chemie, Weinheim: 1985; 118-133
21. Bode AP, Hickerson DHM. Characterization and quantitation by flow cytometry of membranous microparticles formed during activation of platelet suspensions with ionophore or thrombin. Platelets 2000; 11: 259-271
22. Liu J, Farmer JD,Jr, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66: 807-815
23. Clipstone NA, Crabtree GR. Identification of calcineurin as a key signally enzyme in T-lymphocyte activation. Nature 1992; 357: 695-697
24. 2+. Circ Res 1994; 74: 477-484
25. Morris ST, McMurray JJ, Rodger RS, Farmer R, Jardine AG. Endothelial dysfunction in renal transplant recipients maintained on cyclosporine. Kidney Int 2000; 57: 1100-1106
26. Longoni B, Boschi E, Demontis GC, Ratto M, Mosca F. Apoptosis and adaptive responses to oxidative stress in human endothelial cells exposed to cyclosporin a correlate with BCL-2 expression levels. FASEB J 2001; 15: 731-740
27. Martin SJ, Reutelingsperger CP, McGahon AJ et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: Inhibition by overexpression of Bc1-2 and Abl. J Exp Med 1995; 182: 1545-1556
28. Shi J, Heegaard ChW, Rasmussen JT, Gilbert GE. Lactadherin binds selectively to membranes containing phosphatidyl-L-serine and increased curvature. Biochem Biophys Acta 2004; 1667: 82-90
29. Siess W. Molecular mechanisms of platelet activation. Physiol Rev 1989; 69: 58-178
30. Haller H, Spies K, Lindschau C, Quass P, Distler A. The effect of cyclosporine on calcium, protein kinase C, and sodium-proton exchange in platelets. Transplantation 1994; 57: 1516-1520
31. Kwak CS, Mun KC. Production of oxygen free radicals and of hemolysis by cyclosporine. Transplant Proc 2002; 34: 2654-2655
32. Fahr A. Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 1993: 24: 472-495
33. Armstrong VW, Oellrich M. New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine. Clin Biochem 2001; 34: 9-16
34. Reis F, Almeida L, Alcobia T et al. Isosorbide-5-mononitrate treatment prevents cyclosporin A-induced platelet hyperactivation and the underlying nitric oxide-cyctic guanosine-3′, 5′-monophosphate disturbances. Thrombin Reseach 2003; 110: 107-115
35. Knoop C, Haverich A, Fischer S. Immunosuppressive therapy after human lung transplantation. Eur Respir J 2004; 23: 159-171
36. Briffa N, Morris RE. New immunosuppressive regimens in lung transplantation. Eur Respir J 1997; 10: 2630-2637